Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.

Matching Premium IOLs to Visual Lifestyles

From monofocal to full-range solutions, each practice needs comprehensive understanding.

Going Dutch on Acanthamoeba Keratitis

A world-first trial suggests a new medication could beat the disease.

Avoiding Intracorneal Ring Segment Complications

Femtosecond lasers are helping improve refractive results with fewer problems.

Fine-Tuning IOLs After Surgery

Lens power adjustment technology is developing quickly.